טוען...

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC). METHODS: Patients ≥18 years of age...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Thorac Oncol
Main Authors: Zinner, Ralph G., Obasaju, Coleman K., Spigel, David R., Weaver, Robert W., Beck, J. Thaddeus, Waterhouse, David M., Modiano, Manuel R., Hrinczenko, Borys, Nikolinakos, Petros G., Liu, Jingyi, Koustenis, Andrew G., Winfree, Katherine B., Melemed, Symantha A., Guba, Susan C., Ortuzar, Waldo I., Desaiah, Durisala, Treat, Joseph A., Govindan, Ramaswamy, Ross, Helen J.
פורמט: Artigo
שפה:Inglês
יצא לאור: Lippincott Williams & Wilkins 2015
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4276572/
https://ncbi.nlm.nih.gov/pubmed/25371077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000366
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!